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ABSTRACT
H
epatitis C virus (HCV), a single-stranded positive-
sense RNA virus of the Flaviviridae family, infects
more than 170 million people worldwide and is the
leading cause of liver failure in the United States. A unique
feature of HCV is that the viral life cycle depends on
cholesterol metabolism in host cells. This review summarizes
the cholesterol metabolic pathways that are required for the
replication, secretion, and entry of HCV. The potential
application of drugs that alter host cholesterol metabolism in
treating HCV infection is also discussed.
Introduction
Hepatitis C virus (HCV) exacts a heavy toll on public
health. Approximately 3% of the world population is infected
persistently with HCV [1]. According to the Centers for
Disease Control and Prevention, 4.1 million Americans (1.6%
of the United States population) are estimated to be infected
by HCV, 3.2 million of whom become chronically infected [2].
These individuals account for most of the cases of liver failure
in the United States [3]. Owing to its genomic variation, HCV
variants are divided into six genotypes (genotypes 1–6), which
differ from each other by 31% to 33% at the nucleotide level
[4]. Genotype 1 HCV is the most prevalent viral variant found
in the United States. This genotype is also less sensitive to the
current interferon-based therapies, with only about 50% of
patients responding to such treatment [5]. Thus, new
therapeutic strategies to combat HCV infection are needed.
HCV is a single-stranded positive-sense RNA virus of the
Flaviviridae family [6]. The 9.6-kilobase HCV genome encodes
a single polyprotein that is post-translationally processed into
at least ten structural and nonstructural (NS) proteins [7].
The amino-terminal third of the polyprotein encodes the
virion structural proteins: core, E1, and E2, which are
followed by a small integral membrane protein p7 that
functions as an ion channel [8]. The remainder of the genome
encodes the nonstructural (NS) proteins NS2, NS3, NS4A,
NS4B, NS5A, and NS5B. Except for NS2, all of the other NS
proteins are required for efﬁcient viral RNA replication.
These NS proteins (NS3–NS5B) form a viral replication
complex on intracellular membrane vesicles, leading to a
structure termed the membranous web [9,10].
For reasons still unknown, most clinically isolated HCV is
difﬁcult to replicate in cultured cells [7]. Thus, cells harboring
HCV subgenomic replicons are widely used to study HCV
replication. These replicons consist of HCV RNA engineered
to express a selectable marker gene, neo, in place of the
structural protein-coding region. A heterologous viral
internal ribosomal entry site is inserted after the neomycin
resistance cassette to direct translation of viral NS proteins
(NS3–NS5B). When human hepatoma Huh7 cells were
transfected with HCV replicon RNA and selected with G418,
a cell line was established in which HCV RNA was constantly
replicated [11]. This system, although very effective in
studying HCV replication, is not able to produce infectious
HCV particles. Recently, a strain of genotype 2 HCV was
shown to be capable of replicating in Huh7 cells and
producing HCV particles that are infectious to cultured cells
[12–14]. The HCV particles produced from cell culture
(referred to as HCVcc) were able to establish long-term
infections in chimpanzees and in mice containing human
liver grafts [15]. Moreover, virus recovered from these
animals was still infectious in cell culture [15]. For reasons
still unknown, only this strain of HCV or its derivative can be
cultured in Huh7 cells to generate infectious viral particles.
HCV infection is mainly restricted to hepatocytes [1],
which play a vital role in mammalian cholesterol homeostasis.
Like all mammalian cells, hepatocytes are able to acquire
cholesterol through two pathways. Cholesterol can be
synthesized from acetyl-CoA via the mevalonate pathway [16],
which also generates several isoprenoids, including farnesyl
and geranylgeranyl lipids that are covalently attached to the
COOH-terminus of certain proteins [17] (Figure 1). Cells can
also acquire low density lipoprotein (LDL)–associated
cholesterol in serum through LDL receptor–mediated
endocytosis [18]. The LDL receptor binds to LDL particles,
which are internalized via the clathrin-dependent pathway of
receptor-mediated endocytosis. Following endocytosis, the
lipoprotein is degraded in lysosomes and cholesterol in LDL
is released into the cells [18].
In mice, hepatocytes can also acquire a substantial amount
of cholesterol through scavenger receptor class B type I (SR-
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lipoprotein (HDL) particles [19]. In humans, hepatic
cholesterol contributed by HDL is not as signiﬁcant. This is
because humans, but not mice, express cholesteryl ester
transfer protein, which transfers cholesterol from HDL to
LDL or its precursor, very low density lipoprotein (VLDL)
[20]. As a result, the amount of HDL-associated cholesterol is
much lower in humans compared to mice, in which HDL
particles transport most of the plasma cholesterol.
Hepatocytes play a crucial role in regulating mammalian
cholesterol metabolism by exporting cholesterol together
with triglycerides through secretion of VLDL (Figure 2). The
assembly of VLDL begins with synthesis of full length
apolipoprotein B (apoB), a 540-kDa protein that confers
structural integrity to VLDL [21]. Nascent apoB is then fused
with lipid droplets that are rich in triglyceride and cholesteryl
esters in the lumen of the endoplasmic reticulum (ER). While
most cells contain cytosolic lipid droplets, hepatocytes, as well
as other cells producing lipoprotein particles that contain
apoB, have lipid droplets in the lumen of the ER [22]. Fusion
between lipid droplets and apoB requires the activity of
microsomal triglyceride transfer protein (MTP) [23]. Without
MTP-mediated lipid transfer, the secretion of apoB is blocked
and the protein is degraded in cells [24]. The importance of
MTP in VLDL assembly is demonstrated by the observations
that genetic defects in MTP severely reduce VLDL secretion
[25,26]. The resulting VLDL particles are composed of a
hydrophobic core of triglycerides and cholesteryl esters
surrounded by a surface coat containing phospholipids, free
cholesterol, and two predominant lipoproteins, apoB and
apolipoprotein E (apoE). VLDL is secreted out of cells
through exocytosis [27].
Nascent VLDL particles released into plasma are not
ligands for the LDL receptor [28]. These lipoprotein particles
are substrates for lipoprotein lipase, which hydrolyzes the
triglycerides in the core of the lipoprotein particles [29]. A
large proportion (;70%) of the resulting particles, called
intermediate density lipoprotein (IDL) particles, is efﬁciently
removed from plasma by the LDL receptor on hepatocytes
[18]. The remaining IDL particles in the circulation are
converted to LDL particles by a reaction catalyzed by hepatic
lipase, which further reduces the amount of triglycerides in
the lipoprotein particles [30]. Once formed, LDL is taken up
by the LDL receptor on hepatic as well as nonhepatic cells
[18].
Requirement of the Mevalonate Pathway in HCV
RNA Replication
The ﬁrst clue that the mevalonate pathway is involved in
HCV RNA replication was the ﬁnding that treatment of
cultured cells with lovastatin, a cholesterol-lowering drug that
inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)
reductase, the rate-limiting enzyme in the entire mevalonate
pathway [16], inhibited HCV RNA replication [31]. Similar
results were subsequently obtained by others [32–34].
The product of the mevalonate pathway required for HCV
RNA replication turns out to be a geranylgeranyl lipid, as
shown by experiments in which the inhibition of HCV RNA
replication by lovastatin was overcome by the addition of
geranylgeraniol, but not farnesol or cholesterol [31,32].
Geranylgeranyl serves as a lipid substrate for protein
geranylgeranylation, a post-translational modiﬁcation that
covalently attaches geranylgeranyl to various cellular proteins
to facilitate their membrane association [17]. Thus, it appears
that one or more geranylgeranylated proteins are required
for HCV RNA replication. This notion is further supported
by the observation that HCV replication could be blocked by
an inhibitor of geranylgeranyl transferase I [31], an enzyme
that transfers geranylgeranyl groups to cellular proteins [17].
Inasmuch as HCV does not encode a viral protein that
contains the signature COOH-terminal CAAX motif (i.e.,
cysteine-X-X-leucine or isoleucine, in which X is an aliphatic
amino acid) that speciﬁes geranylgeranylation, it was
hypothesized that a geranylgeranylated host protein may be
required for HCV RNA replication. In this regard, a 50-kDa
geranylgeranylated host protein was found to co-
immunoprecipitate with the viral protein NS5A [35]. With the
knowledge of the molecular weight of the protein and the
sequence motif that speciﬁes geranylgeranylation, this
protein was identiﬁed as FBL2 by a bioinformatics approach
[35]. Geranylgeranylation of FBL2 appears to be critical for
doi:10.1371/journal.ppat.0030108.g001
Figure 1. Requirement of the Mevalonate Pathway for HCV Replication
Cells are capable of synthesizing cholesterol through the mevalonate pathway. This pathway also produces geranylgeranyl lipid, which is attached to
the COOH-terminus of FBL2. Geranylgeranylated FBL2 binds to NS5A, an interaction required for HCV RNA replication. Lovastatin, an inhibitor of HMG
CoA reductase, blocks the entire mevalonate pathway. As a result, cells are depleted of geranylgeranyl lipid and replication of HCV is inhibited. PP,
pyrophosphate.
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NS5A depends on geranylgeranylation of FBL2, and this
interaction is required for HCV RNA replication [35] (Figure
1). The exact role played by FBL2 in HCV RNA replication
remains unclear because the physiological function of FBL2 is
not known. FBL2 contains an F-box, a domain known to be
involved in protein ubiquitination [36]. Thus, it is possible
that protein ubiquitination may play a role in HCV RNA
replication. It should be noted that all of the aforementioned
studies used genotype 1 HCV replicons. It is not known
whether geranylgeranylation of host proteins is required for
replication of other genotypes of HCV.
Unlike geranylgeranyl, the requirement of cholesterol for
HCV RNA replication is still under debate. The observation
that addition of cholesterol failed to rescue HCV RNA
replication in the presence of lovastatin suggests that
cholesterol is not directly involved in HCV RNA replication
[31]. However, differing results were obtained when cells were
depleted of cholesterol by treatment with methyl-b-
cyclodextrin, which directly extracts cholesterol from cell
membranes [37]. Under these conditions, HCV RNA
replication is either not affected [38] or reduced by 50% [39].
The inconsistency in these results could arise from a
secondary effect of general cellular toxicity that occurs when
cells are depleted of cholesterol, or from a difference in the
HCV genotype used in these studies.
Requirement for VLDL Assembly in HCV Secretion
Like all positive-strand RNA viruses, HCV RNA replication
occurs in association with cytoplasmic membrane vesicles. In
the case of HCV, these structures (membranous webs) have
been visualized in cultured human hepatoma Huh7 cells that
harbor a subgenomic replicon of HCV [9,40]. Recently,
membrane vesicles containing the HCV replication complex
from Huh7 cells that harbor an HCV replicon were isolated
[41]. Proteomic analysis revealed that these vesicles are
enriched in apoB, apoE, and MTP, proteins known to be
required for the assembly of VLDL [41]. Interestingly, VLDL
synthesis is not required for HCV RNA replication [41]. This
result is consistent with the previous ﬁndings that HCV RNA
can replicate in HeLa and HEK-293 cells [42–44], which do
not produce VLDL. The reason for co-localization of the
HCV replication and VLDL assembly appears to lie in a
requirement for co-assembly or secretion of VLDL and HCV
particles (Figure 2). Thus, When Huh7 cells that constitutively
produce infectious HCV [45] were treated with an MTP
inhibitor or siRNA targeting apoB, the secretion of VLDL
and HCV were both inhibited [41].
Although VLDL secretion is required for HCV production
in cultured cells, this requirement has not been demonstrated
in HCV-infected patients. However, it was shown that HCV
particles circulating in serum are in complex with VLDL [46–
48]. Thus, it appears that HCV particles are attached to or
incorporated into VLDL during the assembly of the
lipoprotein particles and secreted together with VLDL.
Although the nature of the association between HCV and
VLDL remains unclear, studies with HCV isolated from
infected patients suggests that HCV may reside in the lipid-
rich core of VLDL, since delipidation of lipoprotein particles
that contain apoB is required to observe the capsid-like
structures of HCV [46,47]. If HCV indeed hides in the core of
VLDL as suggested [49], it makes the virus unique in that the
doi:10.1371/journal.ppat.0030108.g002
Figure 2. HCV Replicates on ER Membranes Involved in the Assembly of VLDL and Is Secreted Together with VLDL
The assembly of VLDL begins with the synthesis of apoB in the rough ER, resulting in the formation of a VLDL precursor that contains only a small
amount of lipid. In the lumen of the ER, this precursor is fused with lipid droplets (enriched in triglyceride and cholesterol) to generate nascent VLDL.
This reaction is mediated by MTP. The nascent VLDL particles, which contain both apoB and apoE, are secreted into plasma through exocytosis. The ER
membranes involved in the assembly of VLDL are also enriched in HCV NS proteins and RNA. Replication of HCV on these membranes might allow the
virus to attach to or become incorporated into VLDL so that HCV is secreted together with VLDL.
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this model is correct, it will also predict that HCV has to
escape from VLDL-derived lipoprotein particles during viral
entry so that the structural protein E2 can interact with its
cellular receptors, a step required for HCV RNA to enter
cytosol (see below). Exactly what triggers the release of HCV
from the lipoprotein particles is not known. If LDL receptor–
mediated endocytosis is required for HCV entry (see below),
the virus is likely to escape VLDL-derived particles in
endocytic vesicles after the lipoprotein particles are
disassembled during endocytosis. This scenario does not
necessarily contradict the observation that entry of HCVcc
was inhibited by antibodies targeting viral structural protein
E2 [13], since these antibodies might also be included in
endocytic vesicles that contain HCV. It was reported
previously that immunoglobin G is able to enter clathrin-
coated pits nonspeciﬁcally through ﬂuid-phase endocytosis
[50,51]. Thus, these antibodies may block HCV entry by
binding to the viral structural protein after the virus is
released from the lipoprotein particles in endocytic vesicles.
The observation that HCV replicates on membrane vesicles
involved in the assembly of VLDL might also help to explain
the effect of HCV infection on hepatic release of VLDL.
Infection by HCV, particularly the genotype 3 variant, leads
to a reduced rate of VLDL secretion [52,53]. The reduction in
VLDL secretion could arise from inhibition of MTP by viral
proteins. It has been reported that mRNA levels of MTP are
reduced in Huh7 cells harboring HCV replicons [54], and that
transgenic mice expressing HCV core protein in livers have
reduced MTP activity [55]. However, the reduction in MTP
activity has not been demonstrated in cells or patients that
are infected by HCV. The role of reduced VLDL secretion in
HCV infection is currently unknown. It is possible that by
delaying the secretion of VLDL, HCV might have enough
time to replicate and assemble into VLDL.
Besides liver, intestine is the only other tissue that
produces apoB-containing lipoprotein particles. These
particles, called chylomicrons, contain a shorter form of apoB
[56]. Although HCV infection in intestinal cells was reported
in a fraction of HCV-infected patients [57,58], the amount of
HCV detected in intestine was much lower than that in liver
[58]. However, in patients that had HCV infection in
intestine, HCV particles circulating in serum were in complex
with chylomicrons [59]. Thus, it appears that intestinal cells
are able to export HCV, but they might not contain cellular
factors that support efﬁcient entry and/or replication of
HCV.
Requirement of Lipoprotein Receptors for HCV
Entry
HCV enters cells through multiple cellular receptors.
CD81, which directly binds to HCV structural protein E2
[60,61], is required for HCV to enter host cells [13,62].
Interestingly, the amount of CD81 expressed on the cell
surface is affected by cellular cholesterol content. When cells
were depleted of cholesterol by treatment with methyl-b-
cyclodextrin, the amount of CD81 located on plasma
membrane was reduced, resulting in a reduction in HCV
entry [38]. Recently, claudin-1 was identiﬁed as a receptor
functioning at a step later than CD81 [63]. Both CD81 and
claudin-1 have been demonstrated to be required for HCV
entry by experiments showing that viral entry was blocked in
cells that do not express either one of these proteins, and that
reintroduction of the protein into the cells speciﬁcally
restores the viral entry [13,63]. These receptors appear to act
at later steps of HCV entry, because CD81 is not required for
HCV to bind to the cell surface [64] and is not known to
initiate the clathrin-mediated endocytosis that is required for
entry of HCV [65]. Considering the association between HCV
and VLDL-derived lipoprotein particles, lipoprotein
receptors might function at earlier steps in HCV entry.
The LDL receptor, which plays a predominant role in
acquiring VLDL-derived lipoprotein particles through
clathrin-mediated endocytosis in hepatic cells [66,67], has
been reported to be involved in HCV entry. These studies
demonstrated that cellular binding or uptake of HCV
particles isolated from infected patients correlated with LDL
receptor activity on the cell surface [47,68–70]. In contrast to
the results with genuine HCV isolated from serum of HCV-
infected patients, HCV pseudo particles (HCVpp), which
were assembled by displaying HCV structural proteins E1and
E2 onto retroviral core particles, did not require the LDL
receptor for their entry [71]. These results do not argue
against an LDL receptor-mediated uptake of HCV since
HCVpp were produced in HEK-293 cells that do not produce
VLDL [71]. These results also suggest that virus-associated
lipoproteins are required for LDL receptor–mediated
binding of HCV.
Nevertheless, the role of the LDL receptor in HCV entry is
still uncertain, because cellular binding or uptake of HCV in
all of the aforementioned studies did not result in viral
infection. This outcome could be explained by the difﬁculty
of most clinically isolated HCV to replicate in cultured cells
[7]. However, the possibility that LDL receptor–mediated
viral entry does not lead to viral infection cannot be ruled
out. More studies using HCVcc that effectively infect cultured
cells are needed to demonstrate the requirement of the LDL
receptor in HCV entry.
Mutations disrupting the function of the LDL receptor
produce autosomal dominant familial hypercholesterolemia,
which affects 0.2% of the world population [72]. Affected
individuals have elevated plasma levels of LDL cholesterol,
which causes premature coronary atherosclerosis [72].
Mutations in LDL receptors might protect affected
individuals from HCV infection, if the LDL receptor is
indeed involved in HCV entry. An analysis comparing the
frequency of HCV infection in people expressing normal
LDL receptor versus those affected by familial
hypercholesterolemia will be needed to address the question.
Another lipoprotein receptor that is implicated in HCV
entry is SR-BI, which binds to HDL [73] and oxidized LDL
[74,75]. The involvement of SR-BI in HCV entry is indicated
by the observations that entry of HCVcc to cells was blocked
by antibodies directed against SR-BI [38,76] and inhibited by
excessive amounts of oxidized LDL [77]. However, it is not
known whether HCV entry is blocked in cells that do not
express SR-BI. Unlike with the LDL receptor, the interaction
between HCV and SR-BI may not depend on lipoproteins
associated with the virus because the HCV structural protein
E2 directly binds to SR-BI [78]. This notion is further
supported by observations that entry of HCVpp, which does
not associate with VLDL, required SR-BI [79–82].
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Cholesterol Metabolic Pathways in Treating HCV
Infection
A major obstacle in combating HCV infection is that the
ﬁdelity of the viral replication machinery is notoriously low,
thus enabling the virus to quickly develop mutations that
resist compounds targeting viral enzymes [83]. Therefore,
drugs targeting the host proteins required for HCV infection
may be more effective in combating the viral infection. A
unique aspect of HCV that has not been observed in other
viruses is that the entire viral life cycle is associated with
cholesterol metabolism in host cells. Thus, drugs that target
cholesterol metabolism might be useful in treating HCV
infection.
Treatment of cells with statins, the widely used cholesterol-
lowering drugs, has been reported to inhibit HCV RNA
replication [31–34] by depletion of geranylgeranyl lipids
[31,32]. However, the doses of statins currently used to treat
hypercholesterolemia by inhibiting cholesterol synthesis,
thereby stimulating expression of the LDL receptor in the
liver, are not high enough to inhibit the synthesis of
geranylgeranyl lipid. Applying statins to treat HCV will
require much higher doses and would likely cause toxicity in
the liver and other organs.
Another class of drugs designed for treating
hypercholesterolemia blocks the assembly and secretion of
VLDL. These drugs may also be effective in treating HCV
infection because they inhibit production of HCV particles
from infected cells [41]. In this regard, antisense RNA drugs
targeting apoB [84] and several MTP inhibitors [85,86] have
already been tested in clinical trails because of their ability to
block VLDL secretion, thereby lowering the plasma levels of
VLDL triglycerides and LDL cholesterol. Long-term
treatment with MTP inhibitors led to the toxic accumulation
of fat in livers [85,86], thus hampering the approval of these
drugs for the treatment hypercholesterolemia on a long-term
basis. However, short-term treatment (up to several weeks)
reduced the plasma level of VLDL with only minor adverse
effects, which disappeared after drug removal [85]. It will be
interesting to examine whether short-term treatment with
MTP inhibitors is beneﬁcial in treating HCV infection.
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